Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bio-beschikbaarheid van Florotanninen en Carotenoïden na inname van crackers verrijkt met zeewier (BIO-ALGA)

10 november 2026 bijgewerkt door: María Raquel Mateos Briz, National Research Council, Spain

Evaluatie van de biologische beschikbaarheid van florotannines en carotenoïden na inname van crackers verrijkt met Himanthalia elongata

The study aims to evaluate the bioavailability of phlorotannins and carotenoids from the seaweed Himanthalia elongata in healthy individuals after the consumption of a cracker fortified with this plant species. The study consists of an acute, blinded, randomized, controlled, crossover trial in which each participant consumes both the fortified cracker and a control cracker without seaweed. This design allows the comparison of the bioavailability of these compounds when incorporated into a bakery-based food matrix.

Studie Overzicht

Gedetailleerde beschrijving

The BIO-ALGA study is a nutritional intervention designed to evaluate the bioavailability in humans of bioactive compounds present in the brown seaweed Himanthalia elongata, specifically phlorotannins and carotenoids. These compounds have attracted growing interest in the fields of nutrition and functional foods due to their potential antioxidant, anti-inflammatory, and metabolic regulatory properties. Marine macroalgae, and particularly Himanthalia elongata, are recognized as a valuable source of these compounds, in addition to providing dietary fiber, minerals, and other nutrients that may contribute to the prevention of chronic diseases such as obesity, type 2 diabetes, and cardiovascular disorders. However, for these compounds to exert physiological effects in the human body, they must be absorbed during digestion and reach the systemic circulation. Therefore, studying their bioavailability under real consumption conditions in humans is essential.

To address this objective, the study is designed as an acute, randomized, controlled, crossover, and blinded nutritional intervention conducted in healthy adults. Each participant will consume four functional cracker (approx. 20 g) on separate days: one enriched with Himanthalia elongata and another control cracker with identical formulation but without seaweed. The two interventions will be separated by a washout period of at least fifteen days to avoid carryover effects. The expected sample size is at least ten participants, ideally twelve, with balanced representation of men and women. Eligible participants will be healthy adults aged between 18 and 45 years with a body mass index between 18 and 30 kg/m². Exclusion criteria include, digestive diseases, allergies to the ingredients used in the study, current medication or supplement use, hormonal treatments, recent antibiotic consumption, or pregnancy.

The test product consists of four functional cracker weighing approximately 20 g and containing 1 g of freeze-dried Himanthalia elongata powder. This amount ensures the presence of the target bioactive compounds while remaining within safe dietary limits for iodine intake. The formulation includes rice flour, cornstarch, wheat flour, sesame, baking powder, egg and water. A little olive oil was used to enhance the absorption of carotenoids, such as fucoxanthin. Mannitol is used as a sweetener to provide sweetness without substantially increasing caloric content. The placebo bar has the same composition but does not contain seaweed, allowing direct comparison of the absorption of bioactive compounds delivered through the food matrix.

During the seven days prior to each intervention and throughout the study period, participants will be instructed to avoid the consumption of seaweed products. Additionally, they will complete a three-day dietary record before each intervention. On the intervention day, volunteers will attend the Human Nutrition Unit of the Institute of Food Science, Technology and Nutrition (ICTAN-CSIC) after an overnight fast of at least ten hours. A venous cannula will be inserted to allow repeated blood sampling, after which participants will consume the assigned cracker and remain at the research facility for the entire study day under the supervision of the research team. Throughout the day they will receive a standardized polyphenol-free diet to minimize interference with the analytical detection of metabolites derived from the seaweed.

Blood samples will be collected before intake and at multiple postprandial time points (0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 19, and 24 hours) in order to evaluate the plasma kinetics of the absorbed compounds and their metabolites. Approximately 9 mL of blood will be collected at each time point, resulting in a total volume of 99 mL per intervention. Plasma will be separated by centrifugation and stored at -80 °C until analysis. In parallel, urine samples will be collected at defined intervals (-2 to 0 h, 0-3 h, 3-6 h, 6-9 h, and 9-24 h) to assess the urinary excretion of metabolites derived from the bioactive compounds present in the seaweed.

The collected biological samples will be analyzed using high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry with electrospray ionization (HPLC-ESI-QTOF). Targeted metabolomic approaches will be applied to identify and quantify metabolites derived from phlorotannins and carotenoids present in Himanthalia elongata. Based on plasma concentration profiles and urinary excretion patterns, nutritional kinetic parameters such as maximum concentration (Cmax), time to reach maximum concentration (Tmax), and the area under the concentration-time curve (AUC) will be calculated, as well as the proportion of excreted metabolites relative to the ingested dose. This analytical strategy will allow the characterization of the real bioavailability of these compounds under physiological conditions and the identification of potential biomarkers of seaweed consumption.

The study poses minimal risk to participants, mainly limited to mild and transient discomfort associated with blood sampling. The ingredients used in the functional crackers have been carefully selected to ensure food safety and to maintain micronutrient intake, including iodine, within recommended limits. Although the study does not have a direct therapeutic objective, its results are expected to expand current knowledge about the metabolism and bioavailability of seaweed-derived bioactive compounds in humans and to provide scientific evidence supporting the development of functional foods incorporating marine algae with potential health benefits.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

10

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Madrid
      • Madrid, Madrid, Spanje, 28040
        • Institute of Food Science, Technology and Nutrition, Spanish National Research Council (ICTAN-CSIC)

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Body mass index: 18-30 Kg/m2

Exclusion Criteria:

  • Following a vegetarian diet
  • Being pregnant
  • Suffering from digestive diseases (such as irritable bowel syndrome, gastrointestinal ulcers, etc.)
  • Having a history of hypersensitivity or allergies to components of the study foods
  • Following any medication regimen
  • Currently taking or having recently taken antibiotics
  • Having donated blood within the three months prior to the study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Seaweed cracker

Rice flour, wheat flour, cornstarch, Himanthalia elongata (0.94 g), salt, sesame, mannitol, baking powder, olive oil.

Four crackers (20 g) fortified with seaweed Himanthalia elongata

Placebo-vergelijker: Control cracker

Rice flour, wheat flour, cornstarch, salt, sesame, mannitol, baking powder, olive oil

Four crackers (20 g) without seaweed in its composition

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Targeted metabolic analysis of phlorotannins in blood/urine samples
Tijdsspanne: 2 moths

Targeted metabolomic analysis of phlorotannins in plasma and urine samples will be conducted using HPLC-QTOF-MS. Quantification of the concentration (μM) will be carried out employing authentic commercial standards, ensuring accurate and reliable measurement of target compounds.

2 moths

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Targeted metabolic analysis of carotenoids in blood/urine samples.
Tijdsspanne: 2 months

Targeted metabolomic analysis of carotenoids in plasma and urine samples will be conducted using HPLC-QTOF-MS. Quantification of the concentration (μM) will be carried out employing authentic commercial standards, ensuring accurate and reliable measurement of target compounds.

2 months
Maximum concentration in blood of metabolites
Tijdsspanne: 2 month

Calculation of the maximum concentration before cracker intake

2 month
Area under the curve (AUC) of metabolites in blood samples
Tijdsspanne: 2 moths

Metabolite concentrations will be measured at different time points in order to calculate the area under the concentration-time curve.

2 moths
Time to maximum concentration (Tmax)
Tijdsspanne: 2 month

The time required to reach the maximum concentration of the metabolites (Tmax).

2 month
Urinary excretion percentage of metabolites
Tijdsspanne: 2 months

Urinary excretion percentage of metabolites

2 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 maart 2026

Primaire voltooiing (Werkelijk)

16 maart 2026

Studie voltooiing (Werkelijk)

1 juni 2026

Studieregistratiedata

Eerst ingediend

5 maart 2026

Eerst ingediend dat voldeed aan de QC-criteria

30 maart 2026

Eerst geplaatst (Werkelijk)

2 april 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 maart 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • BIO-ALGA
  • COOPB24080 (Ander subsidie-/financieringsnummer: NRC Spain Scientific Cooperation for Development Programme i-COOP 2024)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Individual participant data will be available in open data repositories and may be accessed once the study results are published.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren